AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A)

Item 1.01. Entry Into a Material Definitive Agreement.

The disclosures set forth in Item 1.01 of the Original 8-K are incorporated into this Amendment No. 1 by reference without changes.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



Exhibit
No.      Description
  2.1*     Agreement and Plan of Merger and Reorganization, dated as of December 5,
         2019 among Aevi Genomic Medicine, Inc., Genie Merger Sub, Inc., Second
         Genie Merger Sub, LLC and Cerecor Inc. (including the Form of Contingent
         Value Rights Agreement)
  10.1     Form of Voting Agreement of Aevi Genomic Medicine, Inc. dated December 5,
         2019   (incorporated by reference to Exhibit 10.1 to Current Report on Form
         8-K of Aevi Genomic Medicine, Inc. filed with the Securities and Exchange
         Commission on December 5, 2019)
  10.2     Promissory Note for License Expenses, dated December 5, 2019, by and
         between Cerecor Inc. and Aevi Genomic Medicine, Inc.   (incorporated by
         reference to Exhibit 10.2 to Current Report on Form 8-K of Aevi Genomic
         Medicine, Inc. filed with the Securities and Exchange Commission on
         December 5, 2019)
  10.3     Promissory Note for Operating Expenses, dated December 5, 2019, by and
         between Cerecor Inc. and Aevi Genomic Medicine, Inc.   (incorporated by
         reference to Exhibit 10.3 to Current Report on Form 8-K of Aevi Genomic
         Medicine, Inc. filed with the Securities and Exchange Commission on
         December 5, 2019)
  99.1     Press Release issued by Aevi Genomic Medicine, Inc. dated December 5,
         2019   (incorporated by reference to Exhibit 99.1 to Current Report on Form
         8-K of Aevi Genomic Medicine, Inc. filed with the Securities and Exchange
         Commission on December 5, 2019)
*        The schedules and exhibits to the Agreement and Plan of Merger have been
         omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. Aevi
         will furnish copies of any such schedules or exhibits to the SEC upon
         request.

© Edgar Online, source Glimpses